What is IQ database?
Abiomed’s Impella Quality (IQ) Database is an ongoing, observational, HIPAA-compliant collection of real-world outcomes data on nearly 100% of U.S. Impella patients from more than 1,300 centers. The IQ Database collects outcomes to Impella explant and is used to identify best practices to improve patient outcomes.
IQ data, along with data from the cVAD Study, has helped identify and validate best practices for Impella use associated with improved survival and native heart recovery. These best practices, including use of Impella pre-PCI, reduction of inotropes, early identification of shock, and hemodynamic monitoring with pulmonary artery catheters, have now been validated in multiple publications:
- Catheterization and Cardiovascular Interventions, 2019: New data from the National Cardiogenic Shock Initiative Study(NCSI) on 171 consecutive AMI cardiogenic shock (AMICS) patients from 35 sites demonstrates 72% survival with 98% native heart recovery at discharge.
- Journal of the American College of Cardiology, 2018: Rab, et al., summarizes data from IQ Database, cVAD Study and NCSI and concluded that best practices are associated with improved survival in AMI cardiogenic shock.
- American Heart Journal, 2018: Analysis of 15,259 U.S. patients in the IQ Database demonstrated an improvement in survival to explant from 52% to 59% when Impella was placed pre-PCI (p=0.001).
The IQ Database includes data on more than 36,000 Protected PCI patients who were treated from April 2009 to March 2019. New data, announced in April, shows the mean and median LVEF remains below the ≤35% threshold that is considered depressed, even after Impella received its expanded FDA PMA to include patients with mild or moderately reduced ejection fraction.